Donald C. Sorjonen

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas”.

The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas

Frontiers in Surgery(2020)10.3389/fsurg.2020.00059

N/A

0DataRank · unranked

15 citations

R. Timothy Bentley, David K. Crossman, Jeremy B. Foote, Jennifer W. Koehler, James M. Markert +9 more

Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas

Neurosurgical FOCUS(2021)10.3171/2020.11.focus20844

N/A

0DataRank · unranked

42 citations

R. Timothy Bentley, David K. Crossman, Jeremy B. Foote, Jennifer W. Koehler, James M. Markert +8 more